Clal Insurance Enterprises Holdings Ltd Sells 38,000 Shares of Pfizer Inc. $PFE

Clal Insurance Enterprises Holdings Ltd decreased its stake in Pfizer Inc. (NYSE:PFE) by 1.7% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 2,234,000 shares of the biopharmaceutical company’s stock after selling 38,000 shares during the period. Clal Insurance Enterprises Holdings Ltd’s holdings in Pfizer were worth $62,731,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Evolution Wealth Management Inc. grew its holdings in Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares during the period. Horizon Financial Services LLC raised its holdings in Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares during the period. Godfrey Financial Associates Inc. bought a new position in shares of Pfizer during the fourth quarter worth $26,000. YANKCOM Partnership acquired a new position in shares of Pfizer in the 4th quarter valued at $28,000. Finally, HFM Investment Advisors LLC grew its holdings in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.91 on Wednesday. The company has a fifty day moving average price of $25.17 and a 200 day moving average price of $26.18. The firm has a market cap of $141.97 billion, a PE ratio of 19.02 and a beta of 0.35. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter last year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Analyst Ratings Changes

Several analysts recently commented on the company. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. BMO Capital Markets lowered their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Morgan Stanley raised their price target on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. JPMorgan Chase & Co. cut their price objective on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, July 8th. Finally, HSBC lowered Pfizer from a “buy” rating to a “hold” rating and decreased their price objective for the company from $32.00 to $28.00 in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $28.50.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer could benefit from strength in key non-oncology drugs, with Eliquis and Vyndaqel expected to post better Q2 sales, which may help offset declines elsewhere in the portfolio. What to Watch in Pfizer’s Non-Oncology Portfolio This Earnings Season
• Positive Sentiment: Pfizer is drawing interest as a potential winner in the large weight-loss drug market, supporting longer-term growth expectations if it can compete successfully. Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?
• Neutral Sentiment: Pfizer remains one of the more watched healthcare names among investors, suggesting the stock may see ongoing trading interest ahead of earnings and new updates. Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
• Neutral Sentiment: Recent commentary compared Pfizer with other sub-$50 stocks, but the note was mainly a general screening piece rather than a company-specific catalyst. 1 Stock Under $50 to Target This Week and 2 We Question
• Negative Sentiment: Pfizer faces new international patent lawsuits from Arbutus Biopharma and Genevant Sciences over its mRNA COVID-19 vaccines, creating potential damage claims and injunction risk. Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine
• Negative Sentiment: COVID-related product sales are expected to decline, which may weigh on quarterly results and reinforce concerns about shrinking pandemic-era revenue streams. What to Watch in Pfizer’s Non-Oncology Portfolio This Earnings Season

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.